RESUMEN
In 1994, a standardized dry extract of Ginkgo biloba leaves (SeGb), has been approved by German health authorities for the treatment of primary degenerative dementia and vascular dementia. More than 24 different brands of Ginkgo biloba extract are sold in the United States. Tacrine, also known as tetrahydroaminoacrine (THA), and donepezil are currently the only drugs approved in the United States for the treatment of Alzheimer's disease. Previous studies demonstrated that SeGb and tacrine induce significant pharmacological effects on the brains of young, healthy human males, as determined by bioelectrical activity measurements obtained using the quantitative pharmaco-electroencephalogram (QPEEG) method. The type of central nervous system (CNS) effects we have seen on computer-analyzed EEGs (CEEGs) after administration of tacrine or EGb suggests both are "cognitive activators" which are, as a class of products, characterized by a (prepost) relative increase of 7.5 to 13 Hz ("alpha") and decrease of 1.3 to 7.5 Hz ("delta" and "theta") activity. To determine whether EGb or tacrine had noticeable pharmacological effects on elderly subjects diagnosed with possible or probable Alzheimer's, the present open, uncontrolled trial was conducted. Data from 18 subjects (11 males, 7 females) at an average age of 67.4 years with light to moderate dementia (Mini Mental mean score = 23.7, ranges: 15-29 [Geriatric Depression Scale mean scores = 3.7; range: 3.2-5.4]) were analyzed for this presentation. Each subject was randomly administered a single oral "Test-Dose" of either 40 mg of tacrine or 240 mg of EGb2 in two separate sessions within 3- to 7-day intervals. Before drug administration and at 1- and 3-hour intervals after drug administration, CEEGs were recorded for a minimum of 10 minutes. The CEEGs were analyzed using Period Analysis programs we developed for QPEEG. The results indicated that both EGb and, to a lesser degree, tacrine induced pharmacological effects, as established by QPEEG measurements, in the CNS similar to those previously established in healthy, young subjects. The type of CNS effects produced by EGb (as established by HZI's CEEG psychotropic drug database) in elderly dementia patients were similar to those induced by tacrine responders as well as those seen after the administration of other "cognitive activators" (pramiracetam, vinpocetine, BMY-21502, suloctidil, and lisuride) and anti-dementia drugs approved in the United States or Europe (tacrine, donepezil, nimodipine, piracetam, and oxiracetam) from our database. The results also showed that 240 mg of EGb has typical cognitive activator CEEG profiles (responders) in more subjects (8 of 18) than 40 mg tacrine (3 of 18 subjects). Because of the small sample size, we could not test the hypothesis that subjects who showed cognitive activator-type pharmacological response to the first Test-Dose of EGb or tacrine also exhibit more therapeutic effects (compared to nonresponders) when drugs are administered chronically.
Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Encéfalo/efectos de los fármacos , Demencia Vascular/fisiopatología , Ginkgo biloba , Nootrópicos/farmacología , Extractos Vegetales/farmacología , Plantas Medicinales , Tacrina/farmacología , Anciano , Anciano de 80 o más Años , Electroencefalografía/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
CONTEXT: EGb 761 is a particular extract of Ginkgo biloba used in Europe to alleviate symptoms associated with numerous cognitive disorders. Its use in dementias is based on positive results from only a few controlled clinical trials, most of which did not include standard assessments of cognition and behavior. OBJECTIVE: To assess the efficacy and safety of EGb in Alzheimer disease and multi-infarct dementia. DESIGN: A 52-week, randomized double-blind, placebo-controlled, parallel-group, multicenter study. PATIENTS: Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia, without other significant medical conditions. INTERVENTION: Patients assigned randomly to treatment with EGb (120 mg/d) or placebo. Safety, compliance, and drug dispensation were monitored every 3 months with complete outcome evaluation at 12, 26, and 52 weeks. PRIMARY OUTCOME MEASURES: Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Geriatric Evaluation by Relative's Rating Instrument (GERRI), and Clinical Global Impression of Change (CGIC). RESULTS: From 309 patients included in an intent-to-treat analysis, 202 provided evaluable data for the 52-week end point analysis. In the intent-to-treat analysis, the EGbgroup had an ADAS-Cog score 1.4 points better than the placebo group (P=.04) and a GERRI score 0.14 points better than the placebo group (P=.004). The same patterns were observed with the evaluable data set in which 27% of patients treated with EGb achieved at least a 4-point improvement on the ADAS-Cog, compared with 14% taking placebo (P=.005); on the GERRI, 37% were considered improved with EGb, compared with 23% taking placebo (P=.003). No difference was seen in the CGIC. Regarding the safety profile of EGb, no significant differences compared with placebo were observed in the number of patients reporting adverse events or in the incidence and severity of these events. CONCLUSIONS: EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Demencia por Múltiples Infartos/tratamiento farmacológico , Depuradores de Radicales Libres/uso terapéutico , Extractos Vegetales/uso terapéutico , Actividades Cotidianas , Anciano , Análisis de Varianza , Cognición , Método Doble Ciego , Femenino , Ginkgo biloba , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Psicopatología , Resultado del TratamientoRESUMEN
Natural substances and/or their synthetically developed active ingredients are frequently used in medicine. In psychiatry, two of the most well known natural compounds are reserpine and Ginkgo biloba extract (EGb). EGb is among the most popular over-the-counter medicines in Europe and is also available in the United States, primarily in health food stores. Already the European medical community has recognized EGb as an effective compound in the treatment of cerebral insufficiency. In a pilot bioequivalency study, the effects of three different commercially available EGb products were examined. Findings indicated significant quantitative central nervous system (CNS) effects in, at least, one of the three. Furthermore, the CNS effects of Ginkgold were similar to other psychoactive compounds classified as cognitive activators. Recent studies in which EGb 761 demonstrated therapeutic effects in the treatment of dementia have earned EGb the approval of the German BGA (Bundesgesundheit Amt) for use in the treatment of dementia.
Asunto(s)
Demencia/tratamiento farmacológico , Depuradores de Radicales Libres/uso terapéutico , Extractos Vegetales/uso terapéutico , Adolescente , Adulto , Anciano , Cognición/efectos de los fármacos , Estudios Cruzados , Método Doble Ciego , Electroencefalografía/efectos de los fármacos , Depuradores de Radicales Libres/farmacología , Ginkgo biloba , Humanos , Masculino , Persona de Mediana Edad , Extractos Vegetales/farmacologíaRESUMEN
1. A cross-over single blind study examined the possible central effects of non-opioid analgesic drugs on the trigeminal reflexes. 2. The corneal reflex and blink reflex (R1, R2) were recorded electromyographically and response areas measured in healthy volunteers before and after intramuscular injection of piroxicam (40 mg); and after intravenous injection of lysine acetylsalicylate (500 mg). After the last drug recording the subjects received intravenous naloxone (2 mg) followed 5 minutes later by further reflex testing. Saline was used as a placebo in control experiments. 3. Both analgesics reduced the corneal reflex: piroxicam induced a 27% and lysine acetylsalicylate a 21% a reduction that naloxone did not reverse. Neither drug reduced the early or the late component of the blink reflex. 4. The marked inhibitory changes that the two non-narcotic analgesics produced on the corneal reflex--a nociceptive response--indicate a centrally-mediated action. 5. Naloxone's failure to reverse the induced analgesia argues against opiate receptor mediation.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Reflejo/efectos de los fármacos , Adulto , Aspirina/análogos & derivados , Aspirina/farmacología , Parpadeo/efectos de los fármacos , Córnea/efectos de los fármacos , Estimulación Eléctrica , Potenciales Evocados/efectos de los fármacos , Humanos , Lisina/análogos & derivados , Lisina/farmacología , Naloxona/farmacología , Piroxicam/farmacología , Método Simple Ciego , Nervio Trigémino/efectos de los fármacosRESUMEN
The safety and efficacy of nortriptyline and fluoxetine were compared in a double-blind, randomized, multicenter 5-week trial involving 205 outpatients with acute major depression of moderate severity. Seventy-two nortriptyline and 84 fluoxetine patients completed at least 2 weeks of medication and were included in the efficacy analysis; all patients were evaluated for side effects. Average total scores on the Hamilton Rating Scale for Depression (HAM-D) for both treatment groups declined from 22-23 at baseline to 11.5 at the conclusion of the 5-week period. At Week, 5, 71% of nortriptyline patients and 65% of fluoxetine patients were much or very much improved. Fluoxetine was associated more frequently with nausea (p less than .05), while nortriptyline was associated more frequently with dry mouth (p less than .05). These results are discussed in the context of selecting between nortriptyline and fluoxetine for a particular depressed patient.
Asunto(s)
Trastorno Depresivo/tratamiento farmacológico , Fluoxetina/uso terapéutico , Nortriptilina/uso terapéutico , Adolescente , Adulto , Anciano , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Esquema de Medicación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pacientes Desistentes del Tratamiento , Escalas de Valoración Psiquiátrica , Índice de Severidad de la EnfermedadRESUMEN
Brain mapping has opened important perspectives for the neurophysiological evaluation of patients, for the discrimination of drug effects on the brain and for the study of the relationship between the brain and behavior. Our Dynamic Brain Mapping System is the result of many years of EEG quantification. It was designed as a software-oriented system to favor the largest clinical application and simultaneously stimulate new research objectives. Data collection and analysis procedures are critically important in brain mapping for a good understanding of the results. For clinical use, the maps should answer relevant EEG questions and be interpretable with the consolidated knowledge. Therefore, we have developed a new type of brain mapping technology which is called "Field blending interpolation" mapping offered together with the conventional technology with user-selectable interpolation algorithms. In addition to diagnosis, the use of computer-analyzed EEG and brain mapping can be instrumental in drug monitoring, drug selection and drug discriminations. Prospective studies are, however, required to validate the use of brain mapping in each of these new areas. Spatial analysis is the original goal of brain mapping. The development of a new data collection procedure and analysis will be instrumental in the determination of an adequate time and space resolution.
Asunto(s)
Mapeo Encefálico/métodos , Encéfalo/fisiología , Electroencefalografía , HumanosRESUMEN
A double-blind, placebo- and amitriptyline-controlled comparison study was performed to evaluate the antidepressant efficacy of sertraline, a specific serotonin uptake inhibitor. Patients with DSM-III-defined major depression randomly received either sertraline (N = 149), amitriptyline (N = 149), or placebo (N = 150) once daily for the 8-week study period. The mean final daily medication dose for the all-patients group was 145 mg and 104 mg for the sertraline- and amitriptyline-treatment groups, respectively. As measured by the Hamilton Rating Scale for Depression and the Clinical Global Impressions Scale, both the sertraline and amitriptyline treatment groups showed a significantly greater improvement from baseline (p less than or equal to .001) than the placebo group. The sertraline group had a higher proportion of gastrointestinal complaints and male sexual dysfunction than either the amitriptyline or the placebo group. The amitriptyline group showed a higher proportion of anticholinergic and sedative side effects and dizziness compared with patients who received either sertraline or placebo.
Asunto(s)
1-Naftilamina/análogos & derivados , Atención Ambulatoria , Trastorno Depresivo/tratamiento farmacológico , Antagonistas de la Serotonina/uso terapéutico , 1-Naftilamina/uso terapéutico , Adolescente , Adulto , Anciano , Amitriptilina/efectos adversos , Amitriptilina/uso terapéutico , Trastorno Depresivo/psicología , Mareo/inducido químicamente , Método Doble Ciego , Femenino , Enfermedades Gastrointestinales/inducido químicamente , Humanos , Masculino , Persona de Mediana Edad , Placebos , Escalas de Valoración Psiquiátrica , Sertralina , Disfunciones Sexuales Psicológicas/inducido químicamenteRESUMEN
Two hundred forty-one elderly depressed patients entered the 8-week, double-blind phase of this parallel-group, multicenter study; 161 patients were randomized to receive sertraline (50-200 mg/day) and 80 were randomized to receive amitriptyline (50-150 mg/day). Among evaluable patients, there were no statistically significant differences between treatments in any of the primary efficacy variables: change in total Hamilton Rating Scale for Depression (HAM-D) score (17 items), percentage change in HAM-D score, change in HAM-D Item 1, change in Clinical Global Impressions (CGI) Severity score, change in the Depression Factor of the 56-item Hopkins Symptom Checklist, and the CGI Improvement score at the last visit. Similar results were obtained using data from all patients (intention-to-treat analysis), except that amitriptyline was superior in HAM-D Total score (p = .044). The two drugs produced a similar degree of response: on the basis of the HAM-D criterion, 69.4% of sertraline patients and 62.5% of amitriptyline patients responded, and, on the basis of CGI criterion, 79.5% of sertraline and 73.4% of amitriptyline patients responded. Twenty-eight percent of the sertraline patients withdrew from the study because of a treatment-related side effect and 2.5% (4) because of a laboratory abnormality. In comparison, 35% of the amitriptyline patients withdrew because of treatment-related side effects. Sertraline was associated with a statistically lower frequency of somnolence, dry mouth, constipation, ataxia, and pain and a higher frequency of nausea, anorexia, diarrhea/loose stools, and insomnia; thus, anticholinergic effects were less common and gastrointestinal effects were more common with sertraline than with amitriptyline.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
1-Naftilamina/análogos & derivados , Amitriptilina/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Antagonistas de la Serotonina/uso terapéutico , 1-Naftilamina/química , 1-Naftilamina/farmacología , 1-Naftilamina/uso terapéutico , Anciano , Anciano de 80 o más Años , Amitriptilina/farmacología , Peso Corporal/efectos de los fármacos , Trastorno Depresivo/psicología , Quimioterapia Combinada , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Inventario de Personalidad , Escalas de Valoración Psiquiátrica , Pulso Arterial/efectos de los fármacos , Antagonistas de la Serotonina/química , Antagonistas de la Serotonina/farmacología , SertralinaRESUMEN
In a group of HIV positive young male patients without any significant neuropsychiatric signs, computer-analyzed EEG (CEEG) and Dynamic Brain Mapping evaluations were conducted. These patients, who only had micro-neuropsychiatric symptoms, demonstrated CEEG profiles that more closely resemble those of patients diagnosed as suffering from mild dementia than age-related normals from our CEEG data base. The CEEGs of patients diagnosed as having Acquired Immune Deficiency Syndrome (AIDS), compared to patients with HIV positive, showed greater similarity in CEEG patterns to severely demented patients than to normal control groups. The findings of this pilot study suggest that CEEG may be useful for early determination of the Central Nervous System's (CNS) involvement with the AIDS virus and monitoring the progress of the illness.
Asunto(s)
Complejo SIDA Demencia/diagnóstico , Mapeo Encefálico , Electroencefalografía , Procesamiento de Señales Asistido por Computador , Síndrome de Inmunodeficiencia Adquirida/fisiopatología , Adulto , Femenino , Seropositividad para VIH/fisiopatología , Humanos , Masculino , Proyectos PilotoRESUMEN
In a double-blind, placebo-controlled, crossover study, the CNS effects of intravenously administered diazepam and lorazepam were investigated in anxious subjects through the quantitative pharmaco-EEG (QPEEG) method. For up to 4 1/2 hours following administration the effects of each substance on brain function were measured using computer analyzed EEG recordings (CEEG) and a new technique called Dynamic Brain Mapping. The following observations were made: 1. Both active drugs produce statistically significant CNS effects as measured by CEEG changes. These changes were observed earlier with diazepam than with lorazepam. 2. Although both compounds are classified as anxiolytic by the routine computer EEG data base, the detailed brain mapping technology indicated that the CNS effects of diazepam and lorazepam were quantitatively and qualitatively different. 3. Clinical CNS side-effects (sedation) were seen more frequently with lorazepam than with diazepam. This was consistent with the EEG slowing producing properties of lorazepam. The EEG fast activity which is characteristic for all anxiolytics was established more with diazepam than lorazepam.
Asunto(s)
Mapeo Encefálico/métodos , Encéfalo/efectos de los fármacos , Diazepam/administración & dosificación , Lorazepam/administración & dosificación , Adulto , Trastornos de Ansiedad/tratamiento farmacológico , Sistema Nervioso Central , Diazepam/farmacología , Método Doble Ciego , Electroencefalografía , Humanos , Procesamiento de Imagen Asistido por Computador , Lorazepam/farmacología , Masculino , Distribución AleatoriaRESUMEN
There are a variety of problems in evaluating the bioavailability of psychotropic drugs. Psychotropics have many metabolites; there are discrepancies between peripheral plasma levels and therapeutic effects, and psychotropics must penetrate the blood-brain barrier to have an effect on their target organ. Therefore, "classical" pharmacokinetic evaluation may not be sufficient to determine the bioavailability and bioequivalence of these drugs. Additional and more precise information may be obtained by adding pharmacodynamic procedures to these evaluations. Quantitative pharmaco-EEG (QPEEG), which uses the computer-analyzed electroencephalogram (CEEG), may be the method of choice for determining the pharmacodynamic profiles of psychotropic drugs at the central nervous system (CNS) level. The difficulties in evaluating the bioavailability of psychotropics, as well as the results of several studies that confirm the significance of CEEG as a pharmacodynamic measure, are discussed.
Asunto(s)
Electroencefalografía/instrumentación , Psicotrópicos/metabolismo , Disponibilidad Biológica , Barrera Hematoencefálica , Encéfalo/efectos de los fármacos , Encéfalo/fisiología , Ensayos Clínicos como Asunto , Computadores , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Humanos , Psicotrópicos/farmacología , Pupila/efectos de los fármacos , Pupila/fisiología , Equivalencia Terapéutica , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Oxiracetam, a new substance found to be a nootropic in experimental pharmacological studies, was tested in three clinical trials: a single rising dose tolerance and dose-finding study with quantitative pharmaco-electroencephalogram (pharmaco-EEG) and quantitative pharmacopsychology in healthy volunteers; a dose-finding study, at three dose levels for 3 months, with quantitative pharmaco-EEG in mild to moderate dementia patients; and a safety and efficacy study with increasing dosages for 12 weeks with subjective and objective tests in elderly patients with dementia. In single and repeated oral dosages up to 2,400 mg, oxiracetam is a safe compound. According to HZI Data Bank Classification Systems, oxiracetam is a vigilance-enhancing compound with some effects on spontaneous memory. The therapeutic effect of oxiracetam can be discriminated from placebo, and in comparison with piracetam, oxiracetam exhibits greater improvement in memory factor.
Asunto(s)
Encéfalo/efectos de los fármacos , Demencia/tratamiento farmacológico , Pirrolidinas/uso terapéutico , Método Doble Ciego , Esquema de Medicación , Evaluación de Medicamentos , Electroencefalografía , Humanos , Masculino , Piracetam/uso terapéutico , Pirrolidinas/administración & dosificaciónRESUMEN
Based on computer EEG (CEEG) profiles, in high doses, antidepressant properties of mesterolone, a synthetic androgen, were predicted. In a double-blind placebo controlled study, the clinical effects of 300-450 mg daily mesterolone were investigated in 52 relatively young (age range 26-53 years, mean 42.7 years) male depressed outpatients. During 6 weeks of mesterolone treatment, there was a significant improvement of depressive symptomatology. However, since an improvement was also established during the placebo treatment, no statistically appreciable difference in the therapeutic effects of mesterolone was established compared to placebo. Mesterolone treatment significantly decreased both plasma testosterone and protein bound testosterone levels. Patients with high testosterone levels prior to treatment seem to have had more benefit from mesterolone treatment than patients with low testosterone levels. The degree of improvement weakly correlated to the decrease of testosterone levels during mesterolone treatment.
Asunto(s)
Trastorno Depresivo/tratamiento farmacológico , Dihidrotestosterona/análogos & derivados , Mesterolona/uso terapéutico , Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Electroencefalografía , Hormona Folículo Estimulante/sangre , Humanos , Hormona Luteinizante/sangre , Masculino , Mesterolona/efectos adversos , Persona de Mediana Edad , Monoaminooxidasa/sangre , Escalas de Valoración Psiquiátrica , Testosterona/sangreRESUMEN
Citalopram, a new phthalane derivative and a specific serotonin re-uptake inhibitor in animal pharmacological tests, was evaluated in a double-blind, crossover, quantitative pharmaco-EEG (QPEEGTM) study in healthy human volunteers. The CNS effects of citalopram are linear, dose- and time-related, can statistically be differentiated from placebo, and indicate a rapid onset of effects with short duration. According to the Computer Data Bank, citalopram has a mode of action similar to mood elevators (antidepressants) with fewer sedative properties. Thus the therapeutic action of citalopram is predicted to be similar to desipramine and protriptyline from the tricyclics, and fluvoxamine from non-tricyclics. According to data bank assessment, it is hypothesized that the single antidepressant dose of citalopram is to be more than 25 mg, which should be given t.i.d. in clinical trials.
Asunto(s)
Antidepresivos , Encéfalo/efectos de los fármacos , Propilaminas/farmacología , Adulto , Citalopram , Computadores , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Electroencefalografía , Humanos , Imipramina/farmacología , Tiempo de Reacción/efectos de los fármacos , Relación Estructura-Actividad , Tiofenos/farmacologíaRESUMEN
Direct CNS effects of clonidine (0.2 mg) and propranolol (40 mg and 80 mg) were established in healthy young male subjects within three hours after oral administration. They were demonstrated in two studies using procedures of the Quantitative Pharmaco-EEG (QPEEG) method. Quantitatively, the greatest CNS effects were attained with 0.2 mg clonidine followed by 80 mg, and finally by 40 mg propranolol. Based on the computer-analyzed EEG (CEEG) profiles obtained and using the HZI Research Center CEEG data base, the psychotropic properties of these compounds were predicted. Propranolol, in the 40-mg dose, showed a similarity to vigilance-enhancing compounds, whereas the 80-mg dose and the 0.2-mg dose of clonidine were established as primarily similar to mood-elevating (sedative antidepressant) drugs. However, despite some overall similarities in the mode of action between the high dose of propranolol and the clonidine, some differences in their CNS effects were detected based on their secondary effects (anxiolytic and sedative effects, respectively).
Asunto(s)
Encéfalo/efectos de los fármacos , Clonidina/farmacología , Propranolol/farmacología , Psicotrópicos , Ansiolíticos , Nivel de Alerta/efectos de los fármacos , Electroencefalografía , Emociones/efectos de los fármacos , Humanos , Hipnóticos y Sedantes , MasculinoRESUMEN
1 A double-blind placebo-controlled study of fluvoxamine and imipramine was performed in a group of depressed patients. Twenty-two patients received fluvoxamine (mean dose 101 mg/day), 25 received imipramine (mean dose 127 mg/day) and 22 received placebo. 2 Apart from an increase in the SGOT and SGPT values of four imipramine patients, no statistically significant changes in haematology or urinalysis were judged to be medically relevant. Fluvoxamine exhibited fewer anticholinergic side effects than imipramine. 3 Both fluvoxamine treated patients and imipramine-treated patients exhibited a statistically significant improvement at the end of the 28-day treatment period with respect to the placebo patients, as measured using the Hamilton Rating Scale for Depression, and the Clinical Global Impression Scale. Evaluations of the results of the Beck Depression Inventory and the Profile of Mood States revealed a statistically significant improvement for imipramine patients with respect to placebo at week 4, but not for fluvoxamine patients. It is postulated on the basis of quantitative pharmaco-EEG findings, that the slight superiority of imipramine over fluvoxamine was due to underdosing of the latter.
Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Imipramina/uso terapéutico , Oximas/uso terapéutico , Adulto , Anciano , Antidepresivos/efectos adversos , Ensayos Clínicos como Asunto , Método Doble Ciego , Electroencefalografía , Femenino , Fluvoxamina , Humanos , Imipramina/efectos adversos , Masculino , Persona de Mediana Edad , Oximas/efectos adversos , Escalas de Valoración PsiquiátricaRESUMEN
Antidepressant properties of six compounds were predicted based on their computer-analyzed human electroencephalographical (CEEG) profiles. The clinical investigations with mianserin (GB-94) confirmed the CEEG prediction. This compound has now been marketed as the first antidepressant of which the clinical effects were discovered solely by the quantitative pharmaco-EEG method. As predicted by the CEEG, clinical antidepressant properties of GC-46, mesterolone, and estradiol valerate were observed in preliminary investigations. No extensive studies with definite statistical results were yet carried out with these compounds. No systematic large studies could be conducted with cyclozocine and cyproterone acetate because of the intolerable side effects with these compounds. The optical isomers of mianserin, GF-59 and GF-60, both predicted as antidepressant by the computer EEG data base, have not yet been tested in depressive patients. None of these compounds possess the "typical" pharmacological and/or biochemical profiles of marketed antidepressants. Thus, the discovery of the established antidepressant properties of mianserin (GB-94) by computer analyzed EEG method challenges the well-known biochemical hypotheses of depression and the "classical" development of antidepressant drugs.